Gartley + Additional data release today

NASDAQ:ADVM   Adverum Biotechnologies, Inc.
Friday, October 11, 2019

ADVM is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,

ADVM is set to present additional clinical data for the first cohort of patients (n=6) in the OPTIC phase 1 clinical trial of ADVM-022, intra-vitreal injection gene therapy in wet age-related macular degeneration (wet AMD) at the Retina Sub-specialty Day Program of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting in San Francisco, CA.

NEXT EARNING: Nov 11, 2019

MARKET CAP: $333.254 Million

Technical Analysis:

-Bullish Gartley pattern
-Fibonacci 876 retracement is an important reversal level in high volatility trades.
-Our MS Signal oscillator indicating RSI moving higher and now being a potential good time to buy for a bounce.
-MS CCI Squeeze also indicating that bulls are re-gaining control (over mid-line suggests potential squeeze incoming)

Please like, share, and follow so I can continue finding awesome trades. Check out MS Money Trade Ideas for pre-researched trades to add to your watchlist!! Thanks in advance.

Disclosure: I am long ADVM. I may buy or sell within the next 72 hours. This is not a recommendation to buy or sell. Please do your homework before investing.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.